#diranersen
Latest news and interesting information about diranersen.
Wolfe Research Reaffirms Ionis Stock Outperform Rating
Wolfe Research reiterates Outperform rating on Ionis Pharmaceuticals stock. Analysis of Arrowhead competition and financial results.
Piper Sandler Raises Biogen Target to $225
Piper Sandler raises Biogen price target to $225 from $214. Phase II trial of BIIB080 missed primary endpoint but showed slowing of clinical decline at lowest dose.
Biogen Stock: Alzheimer Drug Shows Promise
Biogen's Alzheimer drug diranersen shows positive Phase 2 results. Stock analysis and future outlook from Bond.az.
...